Velusetrag ( DrugBank: Velusetrag )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
99慢性特発性偽性腸閉塞症1

99. 慢性特発性偽性腸閉塞症


臨床試験数 : 4 薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 4
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-000854-24-IT
(EUCTR)
17/09/202118/10/2021Phase II multicenter clinical trial, with treatment randomly assigned, in which patient nor physician are aware of the assigned treatment, active or placebo, to evaluate efficacy and safety of Velusetrag 15 mg (3 x 5 mg capsule) in patients with Chronic Intestinal Pseudo-Obstruction (CIPO)Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial. - N/A Chronic intestinal pseudo-obstruction (CIPO) is a rare, severe condition characterized by an impairment of coordinated propulsive activity in the intestinal tract resulting in a clinical picture similar to that of mechanical intestinal obstruction, although in the absence of any lesion occluding the gut. CIPO can be idiopathic or secondary.
MedDRA version: 20.0;Level: SOC;Classification code 10017947;Term: Gastrointestinal disorders;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Velusetrag
Product Code: [TD-5108 hydrochloride]
INN or Proposed INN: Velusetrag
Other descriptive name: THRX-199687 hydrochloride
ALFASIGMA S.P.A.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
16Phase 2Spain;Belgium;Italy